Titan Pharmaceuticals - TTNP Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Titan Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" TTNP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TTNP, but not buy additional shares or sell existing shares.
View TTNP analyst ratings or view top-rated stocks.

Titan Pharmaceuticals' stock was trading at $1.02 at the beginning of the year. Since then, TTNP shares have increased by 36.3% and is now trading at $1.39.
View the best growth stocks for 2022 here.

Titan Pharmaceuticals saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 641,800 shares, an increase of 77.1% from the June 30th total of 362,300 shares. Based on an average trading volume of 771,300 shares, the days-to-cover ratio is presently 0.8 days. Currently, 6.7% of the company's shares are short sold.
View Titan Pharmaceuticals' Short Interest.

Titan Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our TTNP earnings forecast.

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) announced its earnings results on Tuesday, March, 30th. The specialty pharmaceutical company reported ($0.86) earnings per share for the quarter, beating analysts' consensus estimates of ($1.33) by $0.47. Titan Pharmaceuticals had a negative net margin of 837.35% and a negative trailing twelve-month return on equity of 127.61%.

Titan Pharmaceuticals shares reverse split before market open on Tuesday, December 1st 2020. The 1-30 reverse split was announced on Monday, November 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Titan Pharmaceuticals investors own include Bionano Genomics (BNGO), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), OrganiGram (OGI), Zosano Pharma (ZSAN), Novan (NOVN), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX) and Pennsylvania Real Estate Investment Trust (PEI).

Titan Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTNP."

Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TTNP stock can currently be purchased for approximately $1.39.

Titan Pharmaceuticals (NASDAQ:TTNP) has a market capitalization of $16.73 million and generates $1.53 million in revenue each year.

Titan Pharmaceuticals employs 11 workers across the globe.

Titan Pharmaceuticals' mailing address is 400 OYSTER POINT BLVD SUITE 505, SAN FRANCISCO CA, 94080. The official website for the company is www.titanpharm.com. The specialty pharmaceutical company can be reached via phone at (650) 244-4990, via email at skilmer@titanpharm.com, or via fax at 650-244-4956.